|MDACC Study No:||2009-0788 (clinicaltrials.gov NCT No: NCT01110473)|
|Title:||A Phase 1 Study Evaluating the Safety and Pharmacokinetics of ABT-348 as monotherapy, and in combination with azacitidine, in Subjects with Advanced Hematologic Malignancies|
|Principal Investigator:||Guillermo Garcia-Manero|
|Treatment Agent:||ABT-348; Azacitidine|
|Study Description:||The goal of this clinical research study is to find the highest tolerable dose |
of ABT-348 that can be given alone or with Vidaza (azacitidine) to patients
with either leukemia or MDS. The safety of this drug or drug combination will
also be studied.
ABT-348 is designed to block proteins that cause cancer cells to grow and
multiply. ABT-348 is also designed to block the formation of new blood vessels
for the tumor. This may cause the cancer cells to die. This is the first study
using ABT-348 in humans.
Azacitidine is designed to block certain proteins in cancer cells whose job is
to stop the function of the tumor-fighting proteins. By blocking these
proteins, the tumor-fighting genes may be able to work better.